期刊文献+

医疗机构开展药械不良反应/事件重点监测工作的思考

Thoughts on key monitoring of adverse drug reactions/events in medical institutions
原文传递
导出
摘要 目的为我国药械不良反应/事件重点监测工作,以及处于监测起步阶段的化妆品不良反应和药物滥用监测工作提供方向.方法概述我国开展药械不良反应/事件重点监测工作的意义和背景,从不同的角度阐明医疗机构开展重点监测工作的必要性和存在的问题,对医疗机构开展重点监测工作提出建议.结果与结论为了更好地开展药械不良反应/事件重点监测工作,需要市场监管部门、卫健委、医疗机构、生产企业等多部门形成合力. Objective Provide direction for the key monitoring work of adverse reactions/events of drugs and equipment in China,as well as the monitoring work of cosmetic adverse reactions and drug abuse,which is in the initial stage of monitoring.Methods Summarize the significance and background of carrying out key monitoring work on adverse reactions/events of drugs and equipment in China,clarify the necessity and existing problems of medical institutions carrying out key monitoring work from different perspectives,and provide suggestions for medical institutions to carry out key monitoring work.Results and Conclusion In order to better carry out the key monitoring work of adverse reactions/events of drugs and equipment,it is necessary to form a joint effort among market supervision departments,health committees,medical institutions,production enterprises,and other departments.
作者 刘莹 陈烁晨 裴丹 刘源 闫舒 Liu Ying;Chen Shuochen;Pei Dan;Liu Yuan;Yan Shu(Zhenjiang adverse drug reaction monitoring center/Zhenjiang food and drug supervision and Inspection Center,Zhenjiang,Jiangsu 212000,China;Zhenjiang Dantu District market supervision and Administration Bureau,Zhenjiang,Jiangsu 212100,China;Jiangsu Provincial Drug Administration Audit and Inspection Center,Nanjing,Jiangsu 210000,China)
出处 《首都食品与医药》 2024年第15期127-129,共3页 Capital Food Medicine
关键词 药械不良反应/事件 重点监测 医疗机构 adverse drug reactions/events key monitoring medical institution
  • 相关文献

参考文献9

二级参考文献78

  • 1刘巍,陈易新.药品不良反应监测与药物警戒[J].中国执业药师,2008,5(8):18-20. 被引量:9
  • 2迟丹怡,王大猷,时颖华,钟明康.医院开展药品不良反应监测的工作思路与方法[J].中国临床药学杂志,2004,13(6):374-376. 被引量:9
  • 3张亮,王大猷.处方事件监测[J].中国药物警戒,2005,2(1):4-6. 被引量:8
  • 4王宗敏,吴晓明.英国处方事件监测制度研究[J].中国药房,2005,16(24):1891-1892. 被引量:4
  • 5FDA.the Senate and House of Representatives of the United States of America, Food and Drug Administration Amendments Act of 2007, [EB/OL]. 2007-09[2011-01].http://frwebgate.access.gpo.gov/cgibin/getdoc.cgi?dbname=110 cong_public_laws&docid=f:pub1085. 110.
  • 6FDA Developing the Sentinel System - A National Resource for EvidenceDevelopment [EB/OL]. 2008-03 [2011-01-12]http.//www. fda.gov/Safety/FDAsSentinelInitiative/ucm089474.htm.
  • 7Platt R, Wilson M, Chan K A, et al. The new Sentinel Network -improving the evidence of medical-product safety[J]. N Engl J Med, 2009,361:645-647.
  • 8FDA, The Sentinel Report, National Strategy for Monitoring Medical Product Safety is available at[EB/OL].[ 2008-03[2011-02] http: //www. fda. gov/downloads/S afety/FDAsSentinellnitiative/UCM 124701pdf.
  • 9Brown J S, Holmes J H, Shah K, et al . Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care[J]. Med Care, 2010,48:Suppl:S45-S51.
  • 10Executive Office of the President President' s Council of Advisors on Science and Technology, Realizing the full potential of health information technology to improve healthcare for Americans: the path forward. Washington, DC: Executive Office of the President [EB/OL]. 2010-12[2011 -01].http://www.whitehouse.govlsites/ default/files/microsites/ostp/pcast-health-it-report.pdf.

共引文献244

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部